Hyro AI vs Labcorp

Side-by-side comparison of AI visibility scores, market position, and capabilities

Labcorp leads in AI visibility (79 vs 36)
Hyro AI logo

Hyro AI

EmergingHealthTech

Healthcare Conversational AI

Hyro AI deploys conversational AI for healthcare systems to automate patient scheduling, FAQ handling, and staff directory navigation across web, app, and phone channels.

AI VisibilityBeta
Overall Score
D36
Category Rank
#526 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
38
Perplexity
37
Gemini
42

About

Hyro builds adaptive conversational AI assistants for healthcare organizations that handle high-volume patient interactions — appointment scheduling, prescription refill requests, symptom FAQ routing, and staff directory navigation — without requiring patients to navigate IVR trees or wait for live agents. Unlike chatbot platforms that rely on rigid decision trees, Hyro uses knowledge graph and NLP technology to answer natural-language questions accurately from existing hospital website content and EHR data.

Full profile
Labcorp logo

Labcorp

LeaderHealthcare Tech

Enterprise

Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.

AI VisibilityBeta
Overall Score
B79
Category Rank
#31 of 596
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
74
Perplexity
82
Gemini
73

About

Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.

Full profile

AI Visibility Head-to-Head

36
Overall Score
79
#526
Category Rank
#31
78
AI Consensus
68
stable
Trend
stable
38
ChatGPT
74
37
Perplexity
82
42
Gemini
73
33
Claude
85
41
Grok
75

Key Details

Category
Healthcare Conversational AI
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Hyro AI
Healthcare Conversational AI

Integrations

Only Labcorp
Labcorp is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.